Skip to product information
1 of 4

Integrin alpha V&beta 6(ITGAV&ITGB6) Protein, His Tag&Tag Free, Human

Integrin alpha V&beta 6(ITGAV&ITGB6) Protein, His Tag&Tag Free, Human

Catalog Number: UA016117 Brand: UA BIOSCIENCE
Price:
Regular price $180 USD
Regular price Sale price $180 USD
Size:

For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Species Human
Synonyms ITGAV&ITGB6,Integrin alpha V&beta 6
Accession NP_002201.1、AAI21179.1
Amino Acid Sequence

ITGAV:Phe31-Val992 with Acidic Tail&His Tag at the C-Terminus ;

ITGB6:Gly22-Asn707 with Basic Tail at the C-Terminus ;

Expression System HEK293
Molecular Weight

100-130kDa&130-180kDa (Reducing)

Endotoxin <0.1EU/μg
Conjugation Unconjugated
Tag His Tag
Physical Appearance Lyophilized Powder
Storage Buffer

PBS, 5% trehalose, pH7.4

Reconstitution

Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation

Stability & Storage

· 12 months from date of receipt,lyophilized powder stored at -20 to -80℃.

· 3 months, -20 to -80℃under sterile conditions after reconstitution.

· 1 week, 2 to 8℃under sterile conditions after reconstitution.

· Please avoid repeated freeze-thaw cycles.

Reference


1.Hirschfield G M, et al. Phase II INTEGRIS-PSC trial of bexotegrast, an αvβ6/αvβ1 integrin inhibitor, in primary sclerosing cholangitis[J]. Journal of Hepatology, 2026, 84(1): 86-98.


2.Ning Y, et al. Multimodal Imaging Demonstrates Antifibrotic Effects of Targeting αvβ6/αvβ1 Integrins in Biliary Fibrosis[J]. Investigative Radiology, 2026, 61(1): 59-67.


3.Dvořáková Bendová K, et al. PET/CT imaging of esophageal cancer targeting tumor cell specific αvβ6-integrin expression[J]. European Journal of Nuclear Medicine and Molecular Imaging, 2025, 53(1): 607-618.

Background

ITGAV (integrin subunit alpha V) and ITGB6 (integrin subunit beta 6) are heterodimeric cell adhesion receptors that non-covalently pair to form the αvβ6 integrin, the only integrin in which β6 exclusively associates with αv. Normally expressed at low levels in healthy epithelia, αvβ6 is markedly upregulated in multiple solid tumors and fibrotic diseases. Functionally, αvβ6 activates latent TGF-β, thereby driving tumor invasion, epithelial remodeling, and immune evasion. Clinically, αvβ6 has emerged as a promising therapeutic and diagnostic target. The dual αvβ6/αvβ1 inhibitor bexotegrast has shown acceptable safety and antifibrotic trends in phase II INTEGRIS-PSC trials for primary sclerosing cholangitis. PET/CT imaging targeting αvβ6 enables staging and treatment guidance in esophageal cancer, while ITGB6 inhibition stimulates potent antitumor immunity in head and neck squamous cell carcinoma and pancreatic adenocarcinoma. Moreover, ITGAV serves as a pan-cancer diagnostic, immunological, and prognostic biomarker. These findings support further development of αvβ6-targeted antibody-drug conjugates, radionuclide theranostics, and combination immunotherapies for precision oncology.

Picture

SDS-PAGE

2μg (R: reducing condition, N:non-reducing condition).

SEC-HPLC

The purity of Integrin alpha V&beta 6(ITGAV&ITGB6) Protein, His Tag&Tag Free, Human is more than 95% determined by SEC-HPLC.



ELISA

Immobilized Fibronectin at 10 μg/mL (100 μL/well) can bind Biotinylated Integrin alpha V&beta 6(ITGAV&ITGB6) Protein, His Tag&Tag Free, Human(Cat. No. UA016117) with a linear range of 0.49-0.83 μg/mL.

Immobilized Integrin alpha V&beta 6(ITGAV&ITGB6) Protein, His Tag&Tag Free, Human(Cat. No. UA016117) at 5 μg/mL (100 μL/well) can bind Biotinylated Latent TGF-Beta 1/TGFB1 His&Avi Tag Protein, Human  with a linear range of 2.2-2.9 ng/mL.